Market Closed -
Other stock markets
|
After market 03:59:59 pm | |||
84.7 EUR | +6.41% | 84.95 | +0.30% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+40.70% | 4.41B | |
+24.17% | 562B | |
-6.31% | 358B | |
+19.85% | 322B | |
+7.80% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.07% | 149B | |
-6.46% | 146B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Laboratorios Farmaceuticos Rovi S A : Spain's Rovi to Manufacture Active Ingredients for Moderna's COVID-19 Jab